As an enthusiast of peptide research and molecular biology, I have spent significant time analyzing the structural complexities of synthetic compounds. One of the most fascinating molecules in this field is the linaclotide peptide sequence. Its unique architecture makes it a subject of great interest for those studying peptide synthesis and structural stability.
The Structural Identity of Linaclotide
Linaclotide is a 14-amino acid synthetic peptide that has garnered attention due to its specific configuration. When reviewing the primary literature, it is consistently identified as a fourteen-membered heterodetic cyclic peptide. This classification is crucial for researchers, as the ring structure is maintained by precise chemical bonding.
The official amino acid sequence is documented as: H–Cys1–Cys2–Glu3–Tyr4–Cys5–Cys6–Asn7–Pro8–Ala9–Cys10–Thr11–Gly12–Cys13–Tyr14.
In the laboratory, observing this 14-amino acid sequence reveals why it is categorized as a 14-amino-acid synthetic cyclic peptide. The stability of the molecule is largely attributed t API | linaclotide o its three intramolecular disulfide LINACLOTIDE bonds, which connect specific cysteine residues (C1–C6, C2–C10, and C5–C13).
Key Characteristics and Synthesis
From a technical perspective, the linaclotide sequence contains three inter-cysteine loops, which are integral to its funct Linaclotide ional geometry. When evaluating high-purity samples, researchers often look for the 14-amino acid residue peptide structure that ensures the molecule remains intact under various conditions.
1. Molecular Formula: C59H79N15O21S6
2. Molecular Weight: Approximately 1,526.8 Da
3. Structural Integrity: The 14 amino acid residues long chain relies on these specific disulfide bridges to maintain its potency and selective interaction with receptors.
During the manufacturing phase, the use of linaclotide linear peptide resin is a standard method for solid-phase synthesis. This process allows for the precise assembly of the 14-amino-acid peptide before the cyclization steps are performed to lock the structure into its final, stable form.
Observations on Peptide Research
In my personal experience, the study of LINACLOTIDE highlights the importance of regioselective synthesis. Because linaclotide is a synthetic peptide drug, maintaining the correct disulfide bridge placement is non-negotiable. If the bonds are misaligned, the structural properties of the 14-amino acid 8Linaclotideis 14amino acidresidues long and is a designed hybrid of these three peptides ( Figure 1A). Similar to STa,linaclotideholds three disulfide Read more synthetic peptide sequence change significantly, rendering the molecule ineffective fo 20 Mar 2026—Linaclotide is a synthetic 14-amino-acid peptide and first The amino acid sequence of linaclotide isH-Cys1-Cys2-Glu3-Tyr4-Cys5Read more r its intended research applications.
Many researchers who work with this molecule note that linaclotide is a potent and selective guanylate cyclase C agonist. While it is technically an Linaclotide | C59H79N15O21S6 | CID 16158208 - PubChem orally administered peptide drug in specific pharmaceutical contexts, those of us in the private research sector focus primarily on its 14-residue structure and its behavior in controlled environments.
Summary of Findings
To summarize, for anyone analyzing the linaclotide peptide sequence, it is essential to focus on:
* The preci Pharmacologic Properties, Metabolism, and Disposition of se H–Cys1–Cys2–Glu3–Tyr4 start of the chain.
* The 14-amino-acid synthetic cyclic peptide arrangement.
* The structural requirement for the three disulfide bridges that give linaclotide its distinct shape.
Whether you are synthesizing the molecule from linaclotide linear peptide resin or conducting structural analysis, the amino acid sequence provides the blueprint for this complex, cysteine-rich molecule. By adhering to these structural parameters, one can better understand why this 14-amino acid residue peptide remains a cornerstone of modern peptide science.